Chinese Tech Company CXMT Targets $85.5 Billion Valuation in Planned IPO

Understand what CXMT's $85.5 billion figure meant, how the IPO was funded, and why its debut changed the valuation.

CXMT is no longer targeting an $85.5 billion valuation in a planned IPO. The Chinese memory-chip company completed the offering and began trading on Shanghai's STAR Market on July 27, 2026, under ticker 688825, according to the Shanghai Stock Exchange listing notice. The $85.5 billion figure represented CXMT's implied market capitalization before trading, not the amount it raised or its value after the debut. The offering valued the company at about 579.2 billion yuan based on its IPO price.

Table of Contents

How the IPO was structured

China's securities regulator approved CXMT's IPO registration on June 5, authorizing the company to proceed under its filed prospectus and underwriting plan. CXMT subsequently priced the offering at 8.66 yuan per share. The company planned to issue 6.69 billion new shares and raise 57.9 billion yuan before any overallotment.

Those shares represented roughly 10% of the company's enlarged share capital, according to the Shanghai Stock Exchange's report on the IPO pricing. The lead underwriter also held a 15% overallotment option, commonly called a greenshoe. Exercising that option would allow additional shares to be sold when demand justified it.

Why CXMT raised the money

The IPO financed more than a valuation milestone. CXMT earmarked the proceeds for memory-wafer production-line upgrades, DRAM technology improvements, and research into future DRAM products. DRAM is the short-term working memory used in computers and other electronic systems. That spending plan matters because semiconductor manufacturers compete through production capacity, manufacturing efficiency, and repeated technology upgrades.

For entrepreneurs, the offering shows how a public listing can fund capital-intensive expansion that private financing may struggle to support at the same scale. CXMT entered the offering after a sharp earnings rebound. Its prospectus reported 2025 revenue of 61.8 billion yuan and net profit of 7.14 billion yuan, following losses in both 2023 and 2024. The profitable year strengthened the IPO case, but it did not erase the company's earlier losses or operating risks.

What happened when trading began

CXMT's shares surged 466% on their first trading day. The rally lifted its estimated market capitalization above $487 billion, the Associated Press reported. That result makes the original headline especially misleading.

The $85.5 billion figure described the valuation implied by the offer price; it was not a continuing target or the company's post-debut market value. The jump also illustrates the difference between IPO pricing and open-market pricing. Underwriters and the issuer set the offer price before trading, while buyers and sellers determine the subsequent price. A dramatic first-day gain shows intense demand, but it does not establish a stable long-term valuation.

What founders and investors should examine

Readers evaluating a major listing should separate figures that headlines often blur: CXMT's case also carries important limitations. Its prospectus identified accumulated unrecouped losses and risks tied to product development, technology, and research spending.

These concerns matter because the company must keep investing while converting technical progress into commercially successful products. CXMT also labeled its estimated revenue and profit for the first half of 2026 as unaudited and expressly said the figures were not earnings guidance. Readers comparing the offering with another startup or semiconductor company should distinguish audited historical results from management estimates before relying on either.

  • Offer price: the price paid for each newly issued share.
  • Gross proceeds: the cash raised before relevant costs.
  • IPO valuation: the market value implied by the offer price.
  • Trading valuation: the market value after public buying and selling begin.
  • Overallotment: additional shares that may be sold under the underwriting arrangement.

You Might Also Like